263 related articles for article (PubMed ID: 28630349)
1. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
3. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
4. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Turturro SB; Najor MS; Yung T; Portt L; Malarkey CS; Abukhdeir AM; Cobleigh MA
Breast Cancer Res Treat; 2019 Sep; 177(2):325-333. PubMed ID: 31209687
[TBL] [Abstract][Full Text] [Related]
5. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
7. A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism.
Thapa N; Chen M; Cryns VL; Anderson R
Cell Rep; 2024 May; 43(5):114119. PubMed ID: 38630589
[TBL] [Abstract][Full Text] [Related]
8. Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Ross RL; Burns JE; Taylor CF; Mellor P; Anderson DH; Knowles MA
PLoS One; 2013; 8(12):e84411. PubMed ID: 24367658
[TBL] [Abstract][Full Text] [Related]
9. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
Simond AM; Rao T; Zuo D; Zhao JJ; Muller WJ
Oncogene; 2017 Oct; 36(43):6059-6066. PubMed ID: 28783168
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition.
Spangle JM; Von T; Pavlick DC; Khotimsky A; Zhao JJ; Roberts TM
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24427-24433. PubMed ID: 32929011
[No Abstract] [Full Text] [Related]
11. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
[TBL] [Abstract][Full Text] [Related]
12. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
Yan LX; Liu YH; Xiang JW; Wu QN; Xu LB; Luo XL; Zhu XL; Liu C; Xu FP; Luo DL; Mei P; Xu J; Zhang KP; Chen J
Int J Oncol; 2016 Feb; 48(2):471-84. PubMed ID: 26676464
[TBL] [Abstract][Full Text] [Related]
13. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ
Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801
[TBL] [Abstract][Full Text] [Related]
14. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract][Full Text] [Related]
15. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.
Schmidt JW; Wehde BL; Sakamoto K; Triplett AA; Anderson SM; Tsichlis PN; Leone G; Wagner KU
Mol Cell Biol; 2014 Apr; 34(7):1363-77. PubMed ID: 24469394
[TBL] [Abstract][Full Text] [Related]
16. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.
Utermark T; Rao T; Cheng H; Wang Q; Lee SH; Wang ZC; Iglehart JD; Roberts TM; Muller WJ; Zhao JJ
Genes Dev; 2012 Jul; 26(14):1573-86. PubMed ID: 22802530
[TBL] [Abstract][Full Text] [Related]
17. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
18. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
19. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.
Oliver MD; Fernández-Acero T; Luna S; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28143957
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium.
Cheung LW; Walkiewicz KW; Besong TM; Guo H; Hawke DH; Arold ST; Mills GB
Elife; 2015 Jul; 4():e06866. PubMed ID: 26222500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]